Catalyst Pharmaceuticals, Inc. (CPRX): Price and Financial Metrics

Catalyst Pharmaceuticals, Inc. (CPRX): $16.73

0.20 (+1.21%)

POWR Rating

Component Grades














  • Quality is the dimension where CPRX ranks best; there it ranks ahead of 94.71% of US stocks.
  • The strongest trend for CPRX is in Quality, which has been heading down over the past 178 days.
  • CPRX ranks lowest in Stability; there it ranks in the 7th percentile.

CPRX Stock Summary

  • The ratio of debt to operating expenses for CATALYST PHARMACEUTICALS INC is higher than it is for about only 9.98% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.19 for CATALYST PHARMACEUTICALS INC; that's greater than it is for just 12.8% of US stocks.
  • Over the past twelve months, CPRX has reported earnings growth of 98.83%, putting it ahead of 86.1% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to CATALYST PHARMACEUTICALS INC, a group of peers worth examining would be OSS, MOMO, CARG, CRTO, and PERI.
  • Visit CPRX's SEC page to see the company's official filings. To visit the company's web site, go to

CPRX Valuation Summary

  • In comparison to the median Healthcare stock, CPRX's price/earnings ratio is 10.62% lower, now standing at 20.2.
  • CPRX's price/sales ratio has moved NA NA over the prior 198 months.

Below are key valuation metrics over time for CPRX.

Stock Date P/S P/B P/E EV/EBIT
CPRX 2023-03-17 7.9 5.6 20.2 13.2
CPRX 2023-03-16 7.8 5.5 20.0 13.1
CPRX 2023-03-15 7.1 5.0 18.2 11.7
CPRX 2023-03-14 8.1 5.7 23.1 15.3
CPRX 2023-03-13 7.9 5.6 22.8 15.0
CPRX 2023-03-10 7.9 5.6 22.8 15.0

CPRX Growth Metrics

    Its year over year cash and equivalents growth rate is now at 40.09%.
  • Its 3 year price growth rate is now at 120.7%.
  • The 2 year price growth rate now stands at 37.23%.
Over the past 33 months, CPRX's revenue has gone up $89,448,663.

The table below shows CPRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 191.755 95.146 66.917
2022-06-30 170.465 75.552 54.498
2022-03-31 153.717 65.036 45.06
2021-12-31 140.833 60.372 39.482
2021-09-30 133.5389 54.30157 41.61013
2021-06-30 126.9016 44.04568 74.621

CPRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CPRX has a Quality Grade of B, ranking ahead of 86.8% of graded US stocks.
  • CPRX's asset turnover comes in at 0.656 -- ranking 47th of 682 Pharmaceutical Products stocks.
  • CHRS, XTNT, and BMY are the stocks whose asset turnover ratios are most correlated with CPRX.

The table below shows CPRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.656 0.858 0.924
2021-03-31 0.691 0.854 1.211
2020-12-31 0.773 0.857 2.263
2020-09-30 0.881 0.860 4.875
2020-06-30 1.045 0.857 6.071
2020-03-31 1.175 0.855 2.426

CPRX Price Target

For more insight on analysts targets of CPRX, see our CPRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.30 Average Broker Recommendation 1.5 (Moderate Buy)

CPRX Stock Price Chart Interactive Chart >

Price chart for CPRX

CPRX Price/Volume Stats

Current price $16.73 52-week high $22.11
Prev. close $16.53 52-week low $6.15
Day low $16.73 Volume 2,765
Day high $16.73 Avg. volume 2,388,481
50-day MA $16.29 Dividend yield N/A
200-day MA $13.79 Market Cap 1.77B

Catalyst Pharmaceuticals, Inc. (CPRX) Company Bio

Catalyst Pharmaceuticals focuses on the development and commercialization of prescription drugs targeting rare neurological diseases and disorders. The company was founded in 2002 and is based in Coral Gables, Florida.

CPRX Latest News Stream

Event/Time News Detail
Loading, please wait...

CPRX Latest Social Stream

Loading social stream, please wait...

View Full CPRX Social Stream

Latest CPRX News From Around the Web

Below are the latest news stories about CATALYST PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPRX as an investment opportunity.

Is It Worth Investing in Catalyst (CPRX) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Catalyst (CPRX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Yahoo | March 17, 2023

3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX)

Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Yahoo | March 16, 2023

Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 4.76% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 15, 2023

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecast of 2023 Total Net Product Revenues, including FYCOMPA, of between $375 Million and $385 Million Recently Acquired Patents Further Strengthens FIRDAPSE Long-Term Commercial Potential to 2037 Actively Pursuing Opportunities to Further Dive

Yahoo | March 15, 2023

7 Core Stocks to Build a Solid Portfolio Around

You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | March 13, 2023

Read More 'CPRX' Stories Here

CPRX Price Returns

1-mo N/A
3-mo -13.54%
6-mo 40.94%
1-year 101.81%
3-year 467.12%
5-year 553.52%
YTD -10.05%
2022 174.74%
2021 102.69%
2020 -10.93%
2019 95.31%
2018 -50.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.755 seconds.